Biotech | October 27, 2025
Novartis to acquire Avidity Biosciences for $12 billion
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
This new facility strengthens Latin America as a collaborative hub
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
Lutavit A/D3 1000/200 NXT provides a combination of vitamin A and vitamin D3 in one formulation
Subscribe To Our Newsletter & Stay Updated
